Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q99678
UPID:
GPR20_HUMAN
Alternative names:
-
Alternative UPACC:
Q99678; Q17R96
Background:
The G-protein coupled receptor 20 (GPCR20) is an orphan receptor characterized by its constitutive G(i) signaling activity, which notably activates cyclic AMP. This receptor is part of the extensive GPCR family, known for their pivotal roles in transducing extracellular signals into cellular responses.
Therapeutic significance:
Understanding the role of G-protein coupled receptor 20 could open doors to potential therapeutic strategies. Its unique signaling pathway highlights its potential as a novel target for drug discovery, aiming to modulate cyclic AMP levels in various physiological contexts.